Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Common Equity (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Common Equity for 9 consecutive years, with $554.3 million as the latest value for Q1 2026.

  • For Q1 2026, Common Equity fell 25.13% year-over-year to $554.3 million; the TTM value through Mar 2026 reached $554.3 million, down 25.13%, while the annual FY2025 figure was $610.0 million, 23.09% down from the prior year.
  • Common Equity hit $554.3 million in Q1 2026 for Bicycle Therapeutics, down from $610.0 million in the prior quarter.
  • Across five years, Common Equity topped out at $873.8 million in Q2 2024 and bottomed at $220.1 million in Q2 2023.
  • Average Common Equity over 5 years is $499.9 million, with a median of $416.0 million recorded in 2023.
  • Year-over-year, Common Equity dropped 29.32% in 2023 and then soared 297.01% in 2024.
  • Bicycle Therapeutics' Common Equity stood at $270.8 million in 2022, then skyrocketed by 36.98% to $370.9 million in 2023, then skyrocketed by 113.8% to $793.1 million in 2024, then dropped by 23.09% to $610.0 million in 2025, then dropped by 9.12% to $554.3 million in 2026.
  • According to Business Quant data, Common Equity over the past three periods came in at $554.3 million, $610.0 million, and $618.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.